ClinicalTrials.gg
RecruitingNCT05367232Updated Feb 7, 2024

A Study of ICP-033 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of ICP-033 tablet in Patients With Advanced Solid Tumors, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-033 Tablets in Patients with Advanced Solid Tumors.

02

Conditions studied

  • Patients With Advanced Solid Tumors
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status of 0-1;
  2. Patients with confirmed locally advanced unresectable or solid tumors;
  3. At least one according to 1.1.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant and lactating women, or women planning to become pregnant during the study through at least 6 months after the last dose of study drug.
  2. Patients with unstable primary central nervous system (CNS) tumors or .
  3. Patients who have active or history of interstitial lung disease or noninfectious pneumonia.
  4. Patients with > 450 ms in males and > 470 ms in females on at screening, or other abnormalities in the ECG at the discretion of the investigator.
  5. Patient with the Medication history and surgical history as stated in the protocol
  6. Those who are unsuitable for blood collection or for blood collection.
  7. Other conditions considered unsuitable for participation in this trial at the discretion of the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    ICP-033 Dose Escalation

    Drug: ICP-033 tablet Administered orally,once a day,every 28 days is a cycle.

    Drug: ICP-033 tablet

Interventions

  • DrugICP-033 tablet

    Administered orally, once a day, 28 days per cycle

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse event (AE) of ICP-033 assessed by NCI-CTCAE V5.0.

    To assess the safety and tolerability of ICP-033 in patients with advanced solid tumors.

    Time frame: through study completion, an average of 2 years

  2. Dose-Limiting Toxicities (DLTs)

    To assess the safety and tolerability of ICP-033 in patients with advanced solid tumors.

    Time frame: through study completion, an average of 2 years

  3. Maximum tolerated dose (MTD)

    To assess the safety and tolerability of ICP-033 in patients with advanced solid tumors.

    Time frame: through study completion, an average of 2 years

  4. Recommended phase II dose (RP2D)

    Time frame: through study completion, an average of 2 years

Secondary outcomes

  1. The maximum plasma concentration observed (Cmax)

    To evaluate the pharmacokinetic (PK) characteristics of ICP-033 in patients with solid tumors.

    Time frame: through study completion, an average of 2 years

  2. Time of maximum observed plasma concentration (Tmax)

    To evaluate the pharmacokinetic (PK) characteristics of ICP-033 in patients with solid tumors.

    Time frame: through study completion, an average of 2 years

  3. Elimination half-life (t1/2)

    To evaluate the pharmacokinetic (PK) characteristics of ICP-033 in patients with solid tumors.

    Time frame: through study completion, an average of 2 years

  4. Area under plasma concentration-time curve (AUC0-t and AUC0-∞)

    To evaluate the pharmacokinetic (PK) characteristics of ICP-033 in patients with solid tumors.

    Time frame: through study completion, an average of 2 years

  5. Apparent clearance (CL/F)

    To evaluate the pharmacokinetic (PK) characteristics of ICP-033 in patients with solid tumors.

    Time frame: through study completion, an average of 2 years

  6. Apparent volume of distribution (Vz/F)

    To evaluate the pharmacokinetic (PK) characteristics of ICP-033 in patients with solid tumors.

    Time frame: through study completion, an average of 2 years

  7. The objective response rate (ORR)

    To evaluate the preliminary anti-tumor activity of ICP-033.

    Time frame: through study completion, an average of 2 years

  8. Duration of response (DoR)

    To evaluate the preliminary anti-tumor activity of ICP-033.

    Time frame: through study completion, an average of 2 years

  9. Progression-free survival (PFS)

    To evaluate the preliminary anti-tumor activity of ICP-033.

    Time frame: through study completion, an average of 2 years

  10. Overall survival (OS)

    To evaluate the preliminary anti-tumor activity of ICP-033.

    Time frame: through study completion, an average of 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Dec 2024, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2022
First posted
May 10, 2022
StartActual
Feb 25, 2022
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05367232
Responsible party
Sponsor
First posted
May 10, 2022
Start date
Feb 25, 2022
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Feb 7, 2024

Study contacts

Feng Bi
Contact
bifeng@medmail.com
+86 028-85423203
Feng Bi
principal investigator · West China Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion